Our Scientific Focus

In recent years, there has been significant growth in precision cancer medicines, which attack specific molecular drivers of patients’ cancers, resulting in higher effectiveness and fewer side effects than ‘traditional’ chemotherapies. The new and exciting field of biology known as epitranscriptomics—which refers to a collection of RNA-modifying proteins (RMPs) that control many aspects of RNA biology—provides a rich opportunity for developing new precision cancer medicines. Our seasoned team at Accent has a proven record of contributing to the development of precision cancer medicines and is applying this approach to RMPs that are critical drivers of specific cancers. Our focus is developing potent drug molecules that selectively inhibit those RMPs that drive cancer – taking extraordinary science into life-changing therapies for patients.

Introduction to epitranscriptomics

Accent President Robert Copeland describes the vast potential of epitranscriptomics

RNA-modifying proteins

A closer look at the novel, emerging biology of epitranscriptomics

RMPs and cancer

A growing body of literature connects a number of RMPs to human cancers